Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

VitaNova Life Sciences (YJGJ) Total Debt (2017 - 2025)

VitaNova Life Sciences (YJGJ) has disclosed Total Debt for 9 consecutive years, with $102000.0 as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Total Debt rose 135.17% year-over-year to $102000.0, compared with a TTM value of $102000.0 through Jan 2025, up 135.17%, and an annual FY2024 reading of $3000.0, down 81.37% over the prior year.
  • Total Debt was $102000.0 for Q1 2025 at VitaNova Life Sciences, down from $128000.0 in the prior quarter.
  • Across five years, Total Debt topped out at $146107.0 in Q1 2021 and bottomed at $3000.0 in Q2 2024.
  • Average Total Debt over 5 years is $48874.9, with a median of $16100.0 recorded in 2023.
  • The sharpest move saw Total Debt crashed 91.72% in 2022, then skyrocketed 688.32% in 2024.
  • Year by year, Total Debt stood at $12100.0 in 2021, then changed by 0.0% to $12100.0 in 2022, then skyrocketed by 34.19% to $16237.0 in 2023, then surged by 688.32% to $128000.0 in 2024, then fell by 20.31% to $102000.0 in 2025.
  • Business Quant data shows Total Debt for YJGJ at $102000.0 in Q1 2025, $128000.0 in Q4 2024, and $55600.0 in Q3 2024.